Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Discovery of Novel Resistance Mechanisms against Regulatory T-cells in Tumour Microenvironment
EF 2014-15
Résumé
Despite consistent progress made by researchers, cancer remains as one of the leading causes of death worldwide. In Canada, cancer contributed to 29.9% of all Canadian deaths in 2011 and the rate of its incidence is continuously rising with growing population. Due to the complex nature of cancer biology, current drugs and therapies used to treat cancer pose many challenges, including severe and unpredictable side-effects. Notably, our own protection system (immune surveillance) is able to specifically clear the heterogeneous population of tumour cells. However, as escape from immune surveillance is frequently observed during cancer progression, helping our immune system to retain its protective function can be a key to combat against tumour development.
Adoptive cell transfer of tumour infiltrating lymphocytes (TILs) is a cancer immune therapy which harnesses our inherit protection process (anti-tumour immunity) to specifically destroy tumour cells. It is reaching its therapeutic potential in multiple malignancies including melanoma and leukemia. However, while TILs demonstrate an anti-tumour immune response, inhibitory cells such as regulatory T (Treg) cells reduce the efficacy of the anti-tumour immune response, therefore serving as a limitation for the immune therapy. Interestingly, several reports have suggested that there are natural mechanisms that are in place that render the anti-tumour cells unresponsive to Treg cells. The aim of our proposed study is to 1) understand the cellular mechanisms behind this Treg resistance process, 2) characterize its anti-tumour immune response in various cancer models, and 3) potentially apply our finding to improving immune therapy for cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331404
Name
Han Seong Jun
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Discovery of Novel Resistance Mechanisms against Regulatory T-cells in Tumour Microenvironment
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antigen; Cancer; Immune Surveillance; Immune Tolerance; Immunogenicity; Immunotherapy; Molecular Mechanism; T-Cells; Tumour Infiltrating Lymphocytes (Tils); Tumour Microenvironment
Abstract
Despite consistent progress made by researchers, cancer remains as one of the leading causes of death worldwide. In Canada, cancer contributed to 29.9% of all Canadian deaths in 2011 and the rate of its incidence is continuously rising with growing population. Due to the complex nature of cancer biology, current drugs and therapies used to treat cancer pose many challenges, including severe and unpredictable side-effects. Notably, our own protection system (immune surveillance) is able to specifically clear the heterogeneous population of tumour cells. However, as escape from immune surveillance is frequently observed during cancer progression, helping our immune system to retain its protective function can be a key to combat against tumour development.
Adoptive cell transfer of tumour infiltrating lymphocytes (TILs) is a cancer immune therapy which harnesses our inherit protection process (anti-tumour immunity) to specifically destroy tumour cells. It is reaching its therapeutic potential in multiple malignancies including melanoma and leukemia. However, while TILs demonstrate an anti-tumour immune response, inhibitory cells such as regulatory T (Treg) cells reduce the efficacy of the anti-tumour immune response, therefore serving as a limitation for the immune therapy. Interestingly, several reports have suggested that there are natural mechanisms that are in place that render the anti-tumour cells unresponsive to Treg cells. The aim of our proposed study is to 1) understand the cellular mechanisms behind this Treg resistance process, 2) characterize its anti-tumour immune response in various cancer models, and 3) potentially apply our finding to improving immune therapy for cancer.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Han, Seong Jun
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~